Comment on Katsarelias, D., et al. "The Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanoma-A Nation-Wide Swedish Population-Based Retrospective Register Study" Cancers 2020, 12 , 3228.

Autor: de Giorgi V; Department of Dermatology, University of Florence, 50132 Florence, Italy., Trane L; Department of Dermatology, University of Florence, 50132 Florence, Italy., Venturi F; Department of Dermatology, University of Florence, 50132 Florence, Italy., Silvestri F; Department of Dermatology, University of Florence, 50132 Florence, Italy., Scarfì F; Department of Dermatology, University of Florence, 50132 Florence, Italy., Gandini S; Department of Experimental Oncology, IEO European Institute of Oncology IRCSS, 20121 Milan, Italy.

Publikováno v: Cancers [Cancers (Basel)] 2020 Dec 30; Vol. 13 (1). Date of Electronic Publication: 2020 Dec 30.

Reply to Comment on Katsarelias, D., et al. 'The Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanoma-A Nation-Wide Swedish Population-Based Retrospective Register Study.'

Autor: Dimitrios, Katsarelias, Hanna, Eriksson, Rasmus, Mikiver, Isabelle, Krakowski, Jonas A, Nilsson, Lars, Ny, Roger, Olofsson Bagge

Publikováno v: Cancers

We thank De Giorgi et al for their interest in our study, and for raising important and relevant questions [...].

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::07972593e8989044fd828110d972f503
https://pubmed.ncbi.nlm.nih.gov/33396857

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Reply to: Pioneering combination: Nivolumab and isolated limb perfusion in melanoma in-transit metastases treatment.

Autor: Holmberg CJ; Sahlgrenska University Hospital, Department of Surgery, Gothenburg, Sweden; Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden., Zijlker LP; The Netherlands Cancer Institute, Department of Surgical Oncology, Amsterdam, the Netherlands; Melanoma Institute Australia, Sydney, New South Wales, Australia., Katsarelias D; Sahlgrenska University Hospital, Department of Surgery, Gothenburg, Sweden; Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Huibers AE; Sahlgrenska University Hospital, Department of Surgery, Gothenburg, Sweden; Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Wouters MWJM; The Netherlands Cancer Institute, Department of Surgical Oncology, Amsterdam, the Netherlands., Schrage Y; The Netherlands Cancer Institute, Department of Surgical Oncology, Amsterdam, the Netherlands., Reijers SJM; The Netherlands Cancer Institute, Department of Surgical Oncology, Amsterdam, the Netherlands., van Thienen JV; The Netherlands Cancer Institute, Department of Medical Oncology, Amsterdam, the Netherlands., Grünhagen DJ; Erasmus Medical Center, Department of Surgical Oncology, Rotterdam, the Netherlands., Martner A; TIMM Laboratory, Sahlgrenska Center for Cancer Research, Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Nilsson JA; Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Harry Perkins Institute of Medical Research, University of Western Australia, Perth, Western Australia, Australia., van Akkooi ACJ; Melanoma Institute Australia, Sydney, New South Wales, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia., Ny L; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., van Houdt WJ; The Netherlands Cancer Institute, Department of Surgical Oncology, Amsterdam, the Netherlands., Olofsson Bagge R; Sahlgrenska University Hospital, Department of Surgery, Gothenburg, Sweden; Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden. Electronic address: roger.olofsson.bagge@gu.se.

Publikováno v: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2024 Dec; Vol. 50 (12), pp. 108653. Date of Electronic Publication: 2024 Sep 07.

The effect of a single dose of nivolumab prior to isolated limb perfusion for patients with in-transit melanoma metastases: An interim analysis of a phase Ib/II randomized double-blind placebo-controlled trial (NivoILP trial).

Autor: Holmberg CJ; Sahlgrenska University Hospital, Department of Surgery, Gothenburg, Sweden; Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden., Zijlker LP; The Netherlands Cancer Institute, Department of Surgical Oncology, Amsterdam, the Netherlands; Melanoma Institute Australia, Sydney, New South Wales, Australia., Katsarelias D; Sahlgrenska University Hospital, Department of Surgery, Gothenburg, Sweden; Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Huibers AE; Sahlgrenska University Hospital, Department of Surgery, Gothenburg, Sweden; Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Wouters MWJM; The Netherlands Cancer Institute, Department of Surgical Oncology, Amsterdam, the Netherlands., Schrage Y; The Netherlands Cancer Institute, Department of Surgical Oncology, Amsterdam, the Netherlands., Reijers SJM; The Netherlands Cancer Institute, Department of Surgical Oncology, Amsterdam, the Netherlands., van Thienen JV; The Netherlands Cancer Institute, Department of Medical Oncology, Amsterdam, the Netherlands., Grünhagen DJ; Erasmus Medical Center, Department of Surgical Oncology, Rotterdam, the Netherlands., Martner A; TIMM Laboratory, Sahlgrenska Center for Cancer Research, Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Nilsson JA; Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Harry Perkins Institute of Medical Research, University of Western Australia, Perth, Western Australia, Australia., van Akkooi ACJ; Melanoma Institute Australia, Sydney, New South Wales, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia., Ny L; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., van Houdt WJ; The Netherlands Cancer Institute, Department of Surgical Oncology, Amsterdam, the Netherlands., Olofsson Bagge R; Sahlgrenska University Hospital, Department of Surgery, Gothenburg, Sweden; Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden. Electronic address: roger.olofsson.bagge@gu.se.

Publikováno v: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2024 Jun; Vol. 50 (6), pp. 108265. Date of Electronic Publication: 2024 Mar 12.